Trial Profile
A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2022
Price :
$35
*
At a glance
- Drugs Mavacamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Acronyms MAVERICK-HCM
- Sponsors MyoKardia
- 07 Nov 2022 Results of a Pooled Safety Analysis from 5 Clinical Trials (PIONEER-HCM, MAVERICK-HCM, EXPLORER-HCM, PIONEER-OLE, MAVA-LTE) presented at the American Heart Association Scientific Sessions 2022
- 13 Nov 2020 According to a MyoKardia media release, data from this study were presented at the American Heart Association's Scientific Sessions 2020.
- 13 Nov 2020 Results presented in a MyoKardia media release.